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Introduction
Antibiotic resistance is threatening public health globally, and colistin remains one of the 
last-resort antibiotics for treating infections because of carbapenem-resistant Enterobacterales. 
Colistin resistance is increasingly being reported in Enterobacterales both worldwide and in 
South Africa, which is of great concern.1,2,3,4,5,6,7,8,9
The predominant mechanism of colistin resistance in Enterobacterales involves 
changes to the phosphate groups of lipid A by adding phosphoethanolamine (PEtN) and/or 
4-amino-4-deoxy-L-arabinose (L-Ara4N), resulting in reduced anionic charge of the 
lipopolysaccharide (LPS). Mutations in the two-component regulatory systems, PhoPQ and 
PmrAB, and inactivation of the mgrB gene are the most common causes of colistin resistance. 
The mobile colistin resistance (mcr-1) gene was first reported in 2016 in China.1 The mcr gene 
encodes a PEtN transferase enzyme, which transfers a PEtN to lipid A, thereby conferring 
resistance to colistin. Additional plasmid-mediated mcr genes, mcr-2-mcr-10 and different 
variants thereof, have since been detected, which also confer colistin resistance.1,2 mcr genes 
have been mostly isolated from Enterobacterales, especially Escherichia coli and Klebsiella 
pneumoniae, which are responsible for both nosocomial and community-acquired (CA) 
infections, including sepsis, pneumonia, urinary tract infections and intra-abdominal 
infections10,11; these organisms are also common gut commensal organisms. Numerous studies 
have detected the mcr gene in isolates from clinical, community and environmental settings.1,2,3,4,5,6
The mcr-1 gene has been identified in clinical isolates from at least 11 hospitals across South 
Africa,7,8,9 as well as in E. coli isolates from outpatients in Gauteng (n = 4) and the Western Cape 
(n = 1).8 The mcr-1 gene has also been detected in E. coli isolated from broiler chickens, a pig and 
final effluents from wastewater treatment plants in South Africa.3,4,5,6 However, there are limited 
data regarding the carriage of colistin-resistant organisms and mcr genes in healthy individuals 
from the community. The presence of mcr genes in the community could serve as a reservoir for 
colistin resistance in clinical settings, leading to difficult and more expensive treatment for 
human bacterial infections, increased hospitalisation, extended hospital stays and sometimes 
death. Gastrointestinal carriage of plasmid-mediated colistin resistance poses additional threat 
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as it may be transferred to other opportunistic pathogens in 
the gut. This study aimed to describe the gastrointestinal 
carriage of colistin-resistant organisms and mcr genes in 
children from Cape Town communities.
Methodology
Study population 
Participants were enrolled in an ongoing Tuberculosis Child 
Multidrug-resistant Preventive Therapy (TB CHAMP) trial, a 
two-arm, cluster-randomised, double-blinded placebo-
controlled phase-3 trial evaluating the efficacy and safety of 6 
months of levofloxacin preventive therapy for treating multi-
drug-resistant tuberculosis (MDR-TB), http://www.isrctn.
com/ISRCTN92634082, in healthy children <5 years of age 
with household exposure to MDR-TB. The first 50 stool 
samples, collected between November 2017 and August 
2018, were used. Children were enrolled from clinics based in 
Khayelitsha and Philippi in urban Cape Town, South Africa.
Sample collection
Stool specimens were collected by nurses from children 
who were enrolled in the trial before commencing study 
treatment using a standard operating procedure. Six 
scoops of formed stool or three scoops of loose stool were 
collected using a 2.5 millilitres (mL) spoon (Lasec, South 
Africa) and mixed several times. Samples were delivered in 
a cooler box with an ice pack (2°C – 8°C) to the National 
Health Laboratory Services (NHLS) microbiology laboratory 
at Tygerberg Hospital and were stored at –80°C. 
Culture-based screening for colistin resistance 
Stool samples were cultured on a MacConkey agar 
(Sigma-Aldrich, South Africa) containing 10 milligrams per 
litre (mg/L) vancomycin (Sigma-Aldrich) and 2 mg/L 
colistin (Sigma-Aldrich) to isolate colistin-resistant E. coli and 
K. pneumoniae using the spread plate method. Distinct 
bacterial colonies were selected based on their morphological 
resemblance to E. coli or Klebsiella spp. on the MacConkey 
agar. Isolates were sub-cultured on a chromogenic UriSelect 
agar (NHLS Media Laboratory, Green Point, South Africa) for 
preliminary identification, and matrix-assisted laser 
desorption/ionisation time-of-flight mass spectrometry 
(MALDI-TOF; Bruker Daltonics, Bremen, Germany) was 
performed to confirm species identification. 
Colistin resistance was confirmed by broth microdilution 
(BMD) following the European Committee on Antimicrobial 
Susceptibility Testing (EUCAST) guidelines and clinical 
breakpoints version 10 (minimum inhibitory concentration 
[MIC] ≤ 2 mg/L: susceptible, MIC > 2 mg/L: resistant). 
Escherichia coli American Type Culture Collection (ATCC) 
25922 and E. coli National Collection of Type Cultures 
(NCTC) 13846 (mcr-1 positive) were used as colistin-
susceptible and -resistant control strains, respectively.
Detection of mobile colistin resistance genes
Genomic deoxyribonucleic acid (DNA) was extracted 
directly from 200 mg of each stool sample using the PSP® Spin 
Stool DNA kit (Stratec Molecular, Germany) according to the 
manufacturer’s instructions. Genomic DNA was extracted 
from colistin-resistant colonies using a crude boil-freeze 
extraction method.12 mcr-1 – mcr-5 genes were detected by 
polymerase chain reaction (PCR), as previously described.13 
Singleplex PCR detection of the mcr-6, mcr-7, mcr-8 and mcr-9 
genes was also performed using previously described primers,14 
newly designed primers (MCR-9YF 5′-ATG CCT GTA CTT 
TTC AGG GTG AAA G-3′ and MCR-9YR 5′-TTC CGC GAA 
TGC CGT GGC TAA-3′) and previously described protocols.7 
No positive controls were available for mcr-6–mcr-9 genes.
Ethical considerations
Ethical approval was obtained from the Health Research 
Ethics Committee (HREC), Stellenbosch University for the 
main trial (M16/02/009) and this sub-study (S17/11/269).
Results
Bacterial growth was observed on the MacConkey agar for 
all 50 stool samples. A total of 70 isolates, 55 E. coli from 
25 participants and 15 K. pneumoniae from six participants, 
were obtained on the MacConkey agar with colistin and 
vancomycin. Escherichia coli and/or K. pneumoniae were 
obtained from the colistin containing media of 30 participants. 
More than one E. coli or Klebsiella spp. colony was isolated 
from some of the participants because of differences in 
colony morphology, and both E. coli and K. pneumoniae were 
isolated from one participant. For 20 of the participants, no 
E. coli or Klebsiella spp. were obtained from the colistin 
containing media. Colistin resistance was confirmed by BMD 
in only 3% (2/70) of the isolates, both of which were E. coli 
(MIC = 4 mg/L). The colistin MICs of the remaining isolates 
were in the range of 0.125 mg/L – 0.5 mg/L. The two colistin-
resistant E. coli were from two separate individuals, and 
therefore, the carriage rates of colistin-resistant E. coli and 
K. pneumoniae were 4% (2/50) and 0% (0/50), respectively. 
The plasmid-mediated mcr-1 to mcr-9 colistin resistance 
genes were not detected in either the colistin-resistant E. coli 
isolates or the DNA extracted directly from the stool samples.
Discussion 
Colistin is regarded as one of the last-resort antibiotics, and 
therefore, any emerging resistance outside of hospital 
settings is of great concern. In South Africa, there is a lack of 
information regarding the carriage of colistin resistance and 
mechanisms of resistance in children and in the community, 
in general. In another Cape Town study, nasopharyngeal 
colonisation with resistant pathogens was reported in 
human immunodeficiency virus (HIV)-positive children, 
with extended-spectrum beta-lactamase production in 50% 
of Enterobacteriaceae15; this poses a risk of becoming 
infected by these resistant organisms. The TB CHAMP trial 
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provided an opportunity to obtain data on gastrointestinal 
carriage of colistin resistance in healthy children from 
communities in Cape Town.
This study showed that carriage of colistin-resistant 
organisms was uncommon in healthy children enrolled from 
local communities, with 4% of participants carrying colistin-
resistant E. coli. The majority (68/70) of the colonies obtained 
on the colistin-containing media were not colistin-resistant 
based on BMD. This could be related to the poor diffusion of 
colistin in agar as previously reported16 or could be influenced 
by the amount of stool cultured, or the abundance of bacteria 
in the stool sample. However, resistance was confirmed by 
BMD, which is considered the only reliable colistin 
susceptibility method.17 A previous study has selected 
colistin-resistant Gram-negative bacteria (GNB) with a higher 
(4 mg/L) colistin concentration in agar18; however, this 
approach has the potential to miss isolates with a borderline-
resistant MIC (2 mg/L – 4 mg/L). Development of a cost-
effective and user-friendly commercial BMD panel for 
colistin susceptibility testing or direct mcr screening could be 
valuable for surveillance purposes. 
None of the mcr-1–mcr-9 genes were detected in any of the 
isolates or stool samples, suggesting that although mcr 
genes have been detected in clinical settings in South 
Africa,7,9 these genes are not widely disseminated in these 
communities. The two colistin-resistant E. coli isolates could 
have chromosomal mutations in pmrA, pmrB, phoP, phoQ, 
eptB or mgrB genes, which lead to L-Ara4N and/or PEtN 
modification of lipid A in the bacterial outer membrane 
resulting in colistin resistance.19,20,21,22,23 In addition, other 
mcr genes (mcr-10) or potentially undescribed, plasmid-
mediated colistin resistance genes could be responsible 
for colistin resistance. 
To the best of our knowledge, this is the first study to 
investigate the carriage of colistin resistance in a South 
African community setting. Colistin resistance in 
communities, especially the dissemination of mcr genes, 
could lead to infections with these resistant organisms, 
which could further spread to hospital settings. Although 
the sample size was small, our data suggest that 
community carriage of colistin-resistant organisms in 
children is uncommon. This also reassures that colistin can 
still be used in this community as a last-resort antibiotic 
when necessary. Ongoing surveillance is needed to 
better understand and estimate the prevalence of colistin 
resistance in the community. 
Conclusion
We report a low carriage rate of colistin-resistant 
Enterobacterales and no plasmid-mediated colistin resistance 
genes in children sampled from the community level. Colistin 
is the last-resort antibiotic for the treatment of multidrug-
resistant GNB, and therefore, there is a need to understand 
the prevalence of colistin resistance in community settings. 
Ongoing surveillance is required in additional community 
settings in order to determine the extent of carriage and its 
contribution to resistance observed in clinical settings.
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